|
|
|
|
|
Click Here to return To Results
|
|
|
|
For all patients,both baseline and end point lesion burden significantly correlated with disability.Increase in MRI lesion area was also significantly correlated with increase in disability over the course of the study,validating serial MRI as an outcome measure with clinical relevance.Since the 8-MIU treatment arm had significantly less lesion accumulation by MRI,a reasonable expectation is that IFNB will limit progression of disability.Confirmed disease progression occurred in fewer patients in the high-dose treatment arm(35%)than in the placebo arm(46%) (P=0.096.)These results support but do not establish an effect of IFNB in limiting progression of disability.This study was not originally powered to demonstrate a treatment effect on disease progression.At these levels of disability,more patients or longer follow-up,or both,would be required. Accordingly,additional clinical trials will be necessary to evaluate the role of IFNB in preventing disability. |
|
(click to filter results - removes previous filter)
disability,neurological
interferon
interferon beta 1-b
MRI
MRI,abnormal
multiple sclerosis
multiple sclerosis,relapsing
multiple sclerosis,treatment of
treatment of neurologic disorder
|
Click Here to return To Results
|
|